Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000003641
JPRN-UMIN000003641
Completed
未知

Clinical study to investigate safety and efficacy on a combined use of rituximab and auto-gamma/delta T cell therapy for CD20-positive B-cell lymphoma. - Clinical study to investigate safety and efficacy on a combined use of rituximab and auto-gamma/delta T cell therapy for CD20-positive B-cell lymphoma.

Japanese Red Cross Medical Center0 sites15 target enrollmentMay 19, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCD20-positive B-cell lymphoma

Overview

Phase
未知
Intervention
Not specified
Conditions
CD20-positive B-cell lymphoma
Sponsor
Japanese Red Cross Medical Center
Enrollment
15
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 19, 2010
End Date
March 1, 2013
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •Patients who have: \- Active enteritis; \- Active autoimmune diseases; \- Active infections; \- Other cancers; \- Other serious complications; \- Continuous systemic administration of steroids.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 1
Clinical study to investigate safety and efficacy on autologous tumor lysate-pulsed dendritic cellsMalignant Glioma
JPRN-UMIN000001903Osaka National Hospital, National Hospital Organization15
Completed
Not Applicable
Clinical study to investigate safety and efficacy on combination of gemcitabine and autologous gamma/delta T cell transfer therapy after resection of pancreatic cancerPancreatic cancer
JPRN-UMIN000000931The University of Tokyo Hospital30
Active, not recruiting
Phase 3
A Clinical Study to Evaluate the Safety and Efficacy of Livercure Tablets on Patients with Liver Cirrhosis.Health Condition 1: K745- Biliary cirrhosis, unspecifiedHealth Condition 2: K745- Biliary cirrhosis, unspecified
CTRI/2022/07/043725Jammi Pharmaceuticals Pvt Ltd
Completed
Phase 2
Clinical study to evaluate the safety and efficacy of cinnamon in the management of non-alcoholic fatty liver diseaseHealth Condition 1: K760- Fatty (change of) liver, not elsewhere classified
CTRI/2021/03/032039Central council for research in Unani medicine New dehli60
Completed
Not Applicable
To study the effect of Tab HFO-O2 in fatty individuals.
CTRI/2016/07/007067Baidyanath Bhavan Pvt Ltd